<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62300">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294877</url>
  </required_header>
  <id_info>
    <org_study_id>110-504</org_study_id>
    <nct_id>NCT02294877</nct_id>
  </id_info>
  <brief_title>A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)</brief_title>
  <acronym>MARS</acronym>
  <official_title>A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this program are: to characterize and describe the Mucopolysaccharidosis
      IV type A (MPS IVA) population as a whole, including the heterogeneity, progression, and
      natural history of MPS IVA; to evaluate the long-term effectiveness and safety of Vimizim®,
      including, but not limited to, the occurrence of serious hypersensitivity reactions,
      anaphylaxis, and changes in antibody status; to help the medical community with the
      development of recommendations for monitoring MPS IVA patients and reports on patient
      outcomes to optimize patient care; to collect data on other treatment paradigms, and
      evaluate the prevalences of their use and their effectiveness; to characterize the effects
      and safety of Vimizim treatment 5 years from enrollment in the Registry for patients under 5
      years of age; to monitor pregnancy exposure, including maternal, neonatal, and infant
      outcomes; and to monitor patients who have completed the MOR-005 and MOR-007 clinical
      trials. These patients will be encouraged to enroll in the applicable Registry Substudy and
      will be monitored using the MOR-005 and MOR-007 assessment schedules, respectively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MARS is a multicenter, multinational, observational disease registry for patients diagnosed
      with Mucopolysaccharidosis Type IVA (MPS IVA). The Registry will collect medical history,
      and clinical and safety assessments every six months, for up to 10 years. The Registry will
      enroll and collect data on patients over a period of at least 8 years from the time of the
      first marketing approval globally and data on individual patients will continue to be
      collected for at least 2 years from the time the last patient was enrolled or until the
      Registry is completed.

      These assessments are designed to further characterize the spectrum of clinical signs and
      symptoms of the disease, and to further characterize the safety profile of Vimizim in a
      broader population. It is not required that patients receive Vimizim to be eligible to
      participate in this Registry.

      In addition, this Registry will collect additional data on patients who have completed the
      MOR-005 and MOR-007 clinical trials. The MOR-005 and MOR-007 clinical trial patients will be
      enrolled into the appropriate Registry Substudy for a minimum of 5 years from the time of
      the patient's enrollment in the MOR-005 clinical study or MOR-007 clinical study. After the
      5 year period, these patients should remain in MARS until the Registry is complete.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Safety of Vimizim treated patients as measured by the incidences of Adverse Events, Serious Adverse Events, and immunology tests</measure>
    <time_frame>10 Years</time_frame>
    <description>Additional safety measures are medications, occurrence of Bone Marrow Transplant/Hematopoietic Stem Cell Transplant, clinical laboratory tests, vital signs, Electrocardiograms, Echocardiograms, immunogenicity results, physical examinations, imaging studies, and cervical spine imaging.
All assessments in this observational study will be carried out per the participating institution's standard of care.
The MARS Annual report will descriptively summarize the safety and outcome measurements for the duration of this voluntary, observational study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of Vimizim as measured by the 6MWT, 3MSCT, RFTs, FEV1, FIVC, FVC, and MVV</measure>
    <time_frame>10 years</time_frame>
    <description>Efficacy of Vimizim as measured by the changes in the 6 minute walk test (6MWT), 3 minute stir climb test (3MSCT), respiratory function tests (RFTs) including forced expiratory volume for 1 second (FEV1), forced inspiratory vital capacity (FIVC), forced vital capacity (FVC), and maximum voluntary ventilation (MVV) and by urinary Keratan Sulfate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The MARS Pregnancy Substudy will collect safety data measured by Adverse Events, Serious Adverse Events, immunology tests, and the infant outcomes as measured by a live birth</measure>
    <time_frame>10 years</time_frame>
    <description>The MARS Pregnancy Substudy will collect safety data on the outcomes of pregnancy in women who receive Vimizim as measured by Adverse Events, Serious Adverse Events, immunology tests, and the infant outcomes as measured by a live birth.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">583</enrollment>
  <condition>Mucopolysaccharidosis IV Type A</condition>
  <condition>Morquio A Syndrome</condition>
  <condition>MPS IVA</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vimizim® (elosulfase alfa)</intervention_name>
    <description>Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)</description>
    <other_name>BMN 110</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood serum; urine samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with MPS IVA disease and patients treated with Vimizim, although patients are not
        required to receive Vimizim to be eligible to participate in this Registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients eligible to participate in this Registry must meet all of the following criteria:

          -  Diagnosed with MPS IVA as confirmed by either N-acetylgalactosamine 6-sulfatase
             (GALNS) enzymatic test or by a diagnostic molecular test

          -  Willing and able to provide written, signed informed consent, or, in the case of
             patients age &lt; 18 years, provide written assent (if required) and written informed
             consent, signed by a legally authorized representative after the nature of the
             Registry has been explained and prior to performance of any Registry-related
             procedures

          -  Willing to undergo assessments to establish baseline data or permit Investigator to
             enter assessment data recorded prior to Registry entry if available in the patient's
             medical records. Entry assessments may include: demographics, medical history,
             urinary keratan sulfate level, urinary protein level, immunogenicity testing, vital
             signs, physical examination, and height and weight

        Patients eligible to participate in the Registry Substudy for MOR-005 must meet all of the
        following criteria:

          -  Must have completed the MOR-005 clinical trial

          -  Willing and able to provide written, signed informed consent, or, in the case of
             patients age &lt; 18 years, provide written assent (if required) and written informed
             consent by a legally authorized representative after the nature of the Registry
             Substudy has been explained and prior to any Registry-related Substudy procedures

          -  Willing to permit Investigator to enter assessment data recorded prior to Registry

          -  Substudy entry if available in the patient's medical records

        Patients eligible to participate in this Registry Substudy for MOR-007 must meet all of
        the following criteria:

          -  Must have completed the MOR-007 clinical trial

          -  Willing and able to provide written, signed informed consent, or in the case of
             patients age &lt; 18 years, provide written assent (if required) and written informed
             consent by a legally authorized representative after the nature of the Registry
             Substudy has been explained, and prior to any Registry-related Substudy procedures

          -  Willing to permit Investigator to enter assessment data recorded prior to Registry
             Substudy entry if available in the patient's medical records

        Exclusion Criteria:

        Patients who meet the following exclusion criterion will not be eligible to participate in
        the Registry or Registry Substudies:

        • Patients currently participating in a BMN 110 (elosulfase alfa) clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simrat Randhawa</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MEDINFO</last_name>
    <phone>615-523-0310</phone>
    <email>MEDINFO@bmrn.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simrat Randhawa</last_name>
    <phone>415-382-7123</phone>
    <email>simrat.randhawa@bmrn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Brady</last_name>
      <phone>501-364-1544</phone>
      <email>bradypatriciam@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Adolfo Garnica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth A Sellars, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Moseley, MS, RD</last_name>
      <phone>323-226-3816</phone>
      <email>kmoseley@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Shoji Yano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Movsesyan, Phd</last_name>
      <phone>714-509-3008</phone>
      <email>nmovsesyan@choc.org</email>
    </contact>
    <investigator>
      <last_name>Raymond Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.I. Dupont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Davey</last_name>
      <phone>302-651-5916</phone>
      <email>LDavey@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Michael Bober, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William MacKenzie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Crosby, CGC</last_name>
      <phone>202-476-6812</phone>
      <email>kacrosby@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>Lindsay Kehoe, CGC</last_name>
      <phone>(202) 476-4549</phone>
      <email>lkehoe@childrensnational.org</email>
    </contact_backup>
    <investigator>
      <last_name>Pranoot Tanpaiboon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasameen Kharazmi</last_name>
      <phone>786-268-1741</phone>
      <email>yazameen.kharazmi@mch.com</email>
    </contact>
    <investigator>
      <last_name>Mislen Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suma Shankar, MD</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Cagle</last_name>
      <phone>404-778-8618</phone>
      <email>scagle@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Suma Shankar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micah Tong</last_name>
      <phone>808-983-6427</phone>
      <email>micah.tong@hawaiipacifichealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Uehara</last_name>
      <phone>800-562-4789</phone>
      <email>karen.uehara@hawaiipacifichealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Laurie Seaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Katz, MS</last_name>
      <phone>312-227-6764</phone>
      <email>rkatz@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Barbara Burton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Charrow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville Research Foundation Inc. - Kosair Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Penny</last_name>
      <phone>502-629-2721</phone>
      <email>slpenn03@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Gordon Gowans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janice Sullivan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kara Goodin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Asamoah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Kritzer, MD</last_name>
      <phone>857-218-4636</phone>
      <email>amy.kritzer@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Kritzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Read</last_name>
      <phone>612-813-6658</phone>
      <email>lisa.read@childrensmn.org</email>
    </contact>
    <contact_backup>
      <last_name>Molly Barrett</last_name>
      <phone>651-220-5730</phone>
      <email>molly.barrett@childrensmn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vikas Bhambani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy J. Mendelsohn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Olson, RN,CNP,APNG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Bedoukian, CGC</last_name>
      <phone>215-590-3692</phone>
      <email>bedoukiane@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Purpus</last_name>
      <phone>(215) 590-4660</phone>
      <email>purpus@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lynne Ierardi-Curto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadene Henderson</last_name>
      <phone>412-692-6065</phone>
      <email>nadene.henderson@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Areeg El-Gharbawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corina Moorehead</last_name>
      <phone>757-401-1132</phone>
      <email>acmoorehead@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Carrie E Mishoe</last_name>
      <phone>304-942-2234</phone>
    </contact_backup>
    <investigator>
      <last_name>Samantha A Vergano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Neumeister-Chisholm, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine G Langley, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela M Casey, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brooke Blessing-Spangler, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin M Helm, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>A. Corina Moorehead, LPN, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carrie E Mishoe, LPN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98145-5005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linnea Brody</last_name>
      <phone>206-884-1264</phone>
      <email>linnea.brody@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Angela Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klane White, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Hale, MN, ARNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Brunner-Krainz, MD</last_name>
      <phone>43-316-385-2813</phone>
      <email>michaela.brunner@klinikum-graz.at</email>
    </contact>
    <investigator>
      <last_name>Michaela Brunner-Krainz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vassiliki Konstantopoulo, MD</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vassiliki Konstantopoulo, MD</last_name>
      <phone>0043 40400-32320</phone>
      <email>Vassiliki.konstantopoulo@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Vassiliki Konstantopoulo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Francois Eyskens, MD</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tine Maes</last_name>
      <phone>0032(0)318214155</phone>
      <email>tine.maes@uaz.be</email>
    </contact>
    <investigator>
      <last_name>Francois Eyskens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's &amp; Women's Centre of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V52 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Thomas</last_name>
      <phone>604-875-3806</phone>
      <email>athomas2@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Lorne Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvia Stockler-Ispiroglu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Sirrs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik For Sjaeldne Handicap</name>
      <address>
        <city>Copenhagen</city>
        <state>Dk-2100</state>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pernille Stroem</last_name>
      <phone>45 21120336</phone>
      <email>pernille.stroem@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Christine Dali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Murphy</last_name>
      <phone>02890636366</phone>
      <email>alison.murphy@belfasttrust.hscni.net</email>
    </contact>
    <investigator>
      <last_name>Fiona Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple Street Children's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eithne Losty</last_name>
      <phone>01 8921903</phone>
      <email>ellen.crushell@cuh.ie</email>
    </contact>
    <investigator>
      <last_name>Ahmad Monavari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen Crushell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ina Knerr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josephine Hughes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple Street Children's University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eithne Losty</last_name>
      <phone>01 8921903</phone>
      <email>eithne.losty@cuh.ie</email>
    </contact>
    <investigator>
      <last_name>Ardeshir Ahmad Monavari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen Crushell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ina Kerr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanne Hughes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Vittorio Emanuele, presidio G Rodolico, Università di Catania</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agata Fiumara, MD</last_name>
      <phone>3900953782478</phone>
    </contact>
    <investigator>
      <last_name>Agata Fiumara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Donati, MD</last_name>
      <phone>0039 055 5662482</phone>
      <email>m.donati@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Alice Donati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <zip>20090</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giusi Sgroi</last_name>
      <phone>390392334915</phone>
      <phone_ext>3525</phone_ext>
      <email>gsgroi@fondazionembbm.it</email>
    </contact>
    <investigator>
      <last_name>Rossella Parini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federico II University Hospital</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Della Casa, MD</last_name>
      <phone>390817462673</phone>
      <email>roberto.dellacasa@unin.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Della Casa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frits Wijburg, MD</last_name>
      <phone>31 20 5662303</phone>
      <email>f.a.wijburg@amc.nl</email>
    </contact>
    <investigator>
      <last_name>Frits Wijburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ana Van der Ploeg, MD</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Van der Ploeg, MD</last_name>
      <phone>31 107032083</phone>
    </contact>
    <investigator>
      <last_name>Ana Van der Ploeg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heriberto Roman-Berrios</last_name>
      <phone>787-999-9453</phone>
      <email>heriberto.roman@sanjorgechildrenshospital.com</email>
    </contact>
    <investigator>
      <last_name>Juan A Santiago-Cornier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Stewart</last_name>
      <phone>0121 333 9907</phone>
      <email>Alice.stewart@bch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Saikat Santra, MA/MB/BCh</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suresh Vijayaraghavan, MB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital Birmingham</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaun Bolton</last_name>
      <phone>44121-371-6795</phone>
      <email>shaun.bolton@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tarekegn G Hiwot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte Dawson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Lansdell</last_name>
      <phone>020-7794-0500</phone>
      <phone_ext>33476</phone_ext>
      <email>erika.lansdell@nihr.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Derralynn Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Uma Ramaswami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Atulkumar Mehta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Jastrub</last_name>
      <phone>0203 448 3607</phone>
      <email>roman.jastrub@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Elaine Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robin Lachmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Brodie</last_name>
      <phone>0207-405-9200</phone>
      <phone_ext>6894</phone_ext>
      <email>ruth.brodie@gosh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Maureen Cleary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Mercer, MBBCH, MRCPCH</last_name>
      <phone>0044 161 7012138</phone>
      <email>elisabeth.jameson@cmft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Jameson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Jones, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Broomfield, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford Greater Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Meehan</last_name>
      <phone>0161 206 4192</phone>
      <email>marie.meehan@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Christian Hendriksz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reena Sharma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gisela Wilcox, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Jovanovic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>October 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis IV</mesh_term>
    <mesh_term>Osteochondrodysplasias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
